Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmuneRegen BioSciences and DelSite Biotechnologies, a wholly owned subsidiary of Carrington Laboratories have signed an agreement to work together to design and develop novel new treatments to prevent the spread of pandemic flu.
Subscribe to our email newsletter
The agreement contemplates that DelSite’s patented GelSite polysaccharide polymer may facilitate the administration and enhance the activity of Homspera, ImmuneRegen’s experimental candidate which has previously demonstrated effectiveness as an anti-influenza agent and vaccine adjuvant when administered intranasally.
The company believes that the GelSite polymer could facilitate self-administration of Homspera by virtue of its physical characteristics and its ability to enable time-delayed release of the active drug. The GelSite polymer has been shown to be well tolerated in animal studies and is classified as ‘generally regarded as safe’, when administered either topically or orally.